IMMUNOTECH BIOPHARM LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.32 HKD | -3.21% |
|
+2.79% | -33.60% |
| Mar. 29 | Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023 | MT |
| Mar. 28 | Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
ETFs positioned on Immunotech Biopharm Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.77% | 4 M€ | -27.92% | ||
| 0.02% | 2 M€ | -.--% |
Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.60% | 226M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +5.09% | 22.94B | |
| -12.15% | 22.34B | |
| -6.26% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +38.61% | 12.63B | |
| +313.59% | 8.49B |
- Stock Market
- Equities
- 6978 Stock
- Funds and ETFs Immunotech Biopharm Ltd